Liver Cancer
Conditions
Keywords
Real-World Study, Immunotherapy, Retrospective Study
Brief summary
Hepatocellular carcinoma (HCC) is a common global malignancy. In China, the disease burden is substantial: HCC ranks fifth in cancer incidence and third in mortality, with a 5-year relative survival of only 14.4%. In Northeast China's cold regions, metabolic diseases such as hypertension, hyperlipidemia, and diabetes are prevalent and may influence HCC prognosis. Recently, PD-1/PD-L1 inhibitor-based combination regimens (with targeted therapy, chemotherapy, or locoregional treatment) have achieved major breakthroughs, significantly extending overall and progression-free survival. These regimens have become the first-line backbone for unresectable HCC. Investigating their real-world effectiveness and safety is critical for optimizing regional treatment strategies.
Detailed description
This open-label, multicenter, retrospective real-world study aims to enroll 1000 patients with confirmed HCC, intrahepatic cholangiocarcinoma, or mixed cell carcinoma who have long-term residence in Northeast China (annual mean temperature 1.6°C-10°C) and have received immune-based combination therapy. Patient data will be retrospectively collected from January 1, 2020, to December 31, 2025. Based on treatment stage, patients will be assigned to 1 of 4 cohorts: perioperative (neoadjuvant/adjuvant), locoregional therapy, first-line advanced, or later-line advanced. This noninterventional study does not alter routine clinical practice; data are derived from medical records. The primary objective is to evaluate real-world effectiveness and safety of immune-based combinations. The primary endpoint is overall survival (OS). Secondary endpoints include objective response rate (rwORR), progression-free survival (rwPFS), disease control rate (rwDCR), duration of response (rwDOR), and safety (AE, SAE, irAE rates). The findings aim to provide real-world evidence for immunotherapy in HCC across Northeast China.
Interventions
DRUGImmune Checkpoint Inhibitors
Immunotherapy: PD-1 inhibitors (e.g., pembrolizumab, nivolumab, camrelizumab, sintilimab) and other immune checkpoint inhibitors; PD-L1 inhibitors (e.g., atezolizumab, durvalumab, adebrelimab) and other immune checkpoint inhibitors. Targeted therapy: Lenvatinib, donafenib, sorafenib, apatinib, bevacizumab, and other targeted therapy agents. Chemotherapy: Oxaliplatin-based and other systemic chemotherapy regimens. Locoregional therapy: Transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), radiofrequency ablation (RFA), microwave ablation (MWA), percutaneous ethanol injection (PEI), cryoablation, external beam radiotherapy (EBRT), and internal radiotherapy. Other regimens selected/recommended by investigators: Including but not limited to traditional Chinese medicine preparations and other antitumor therapies. Treatment options include immunotherapy alone, immunotherapy combined with targeted therapy, or immunotherapy combined with locoregional thera
Sponsors
Harbin Medical University
Liaoning Cancer Hospital & Institute
China-Japan Union Hospital, Jilin University
First Affiliated Hospital of Harbin Medical University
The Second Affiliated Hospital of Harbin Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Patients with a clinically confirmed diagnosis of primary hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or combined hepatocellular-cholangiocarcinoma, with measurable tumor lesions. 2. Patients who have long-term residence in the cold regions of Northeast China, specifically in provinces with an annual mean temperature between 1.6°C and 10°C: Heilongjiang Province, Jilin Province, and selected cities in Liaoning Province. 3. Patients who have received an immune-based therapy regimen. 4. Patients with complete clinical data who meet the enrollment criteria, retrospectively collected from January 1, 2020, to December 31, 2025.
Exclusion criteria
1. Patients with concurrent other malignancies. 2. Patients who are confirmed pregnant or breastfeeding. 3. Any other conditions that, in the investigator's judgment, make the patient unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival | From start of treatment to death or last follow-up, assessed up to 36 months. | Time from initiation of immune-based combination therapy to death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Real-World Progression-Free Survival (rwPFS) | From start of treatment to progression or death, assessed up to 36 months. | Time from treatment initiation to first documented disease progression or death, based on real-world clinical assessment. |
| Real-World Objective Response Rate (rwORR) | From start of treatment to end of treatment, assessed up to 36 months. | Proportion of patients with best overall response of complete response (CR) or partial response (PR) based on real-world clinical assessment. |
| Real-World Best Overall Response (rwBOR) | From start of treatment to end of treatment, assessed up to 36 months. | Best tumor response recorded during treatment, including CR, PR, SD, PD, or NE based on real-world clinical assessment. |
| Real-World Disease Control Rate (rwDCR) | From start of treatment to end of treatment, assessed up to 36 months | Proportion of patients with best overall response of CR, PR, or stable disease (SD) based on real-world clinical assessment. |
| Real-World Duration of Response (rwDOR) | From first response to progression or death, assessed up to 36 months. | Time from first documented CR or PR to disease progression or death, assessed in patients who achieved objective response. |
| AE Incidence | From first dose to 90 days after last dose of immunotherapy or 30 days after last dose of antiangiogenic agents, whichever is later. | Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and immune-related adverse events (irAEs), graded by NCI-CTCAE v6.0. |
Countries
China
Outcome results
None listed